Losing weight is rarely straightforward
Tirzepatide Tirzepatide (Mounjaro, Eli Lilly) is a dual incretin agonist that targets both GLP-1 and GIP receptors
As I began to dig into the science, first for myself, then for my patients, it became clear that menopause is not just about hot flashes and skipped periods
Tirzepatides dual agonist function targets both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor
These drugs directly activate GLP-1 receptors, producing sustained appetite suppression, slower digestion to keep someone feeling full longer, and regulation of blood sugar
In the short-term simvastatin stratum, ALC reduced HOMA-IR along with a significant decrease in insulin concentration, suggesting a possible initial metabolic effect of the study drug